Our People

 

Michael Stewart - Non-Executive Chairman

Michael Stewart joined the Board as a Non-Executive Director in June 2009 and was appointed to the position of Chairman on 1 January 2014. He has a broad corporate and management background and has been extensively involved in bilateral donor funded and World Bank co-financed Aid Projects in under-developed countries.

  

Stephen Carter - Chief Executive Officer

Stephen Carter joined the company in October 2010 as Chief Executive Officer and a Director.  He has over 25 years pharmaceutical industry experience and has held a variety of senior positions with publicly listed companies including roles as both Chairman and Managing Director. Amongst his previous roles, Stephen was Chairman of Hollista Colltech Ltd and DelMedica Ltd; and he was Managing Director of ASX-listed Solbec Pharmaceuticals Ltd. He has extensive contacts and experience in the financial markets and the pharmaceutical industry and is well equipped to lead executive management through the company's product commercialisation phase. 

 

Joseph Ohayon - Chief Financial Officer, Company Secretary & Executive Director

Joseph Ohayon joined the company in July 2010 as the Chief Financial Officer and in March 2011 he took over the role of Company Secretary and then became an Executive Director and  member of the Board in December 2012.  He has over 20 years experience in financial roles including 12 years within health-related industries. Joseph qualified as a Chartered Accountant in the UK and graduated with a Masters of Business Administration in International Business from Murdoch University in 2007.  

 

Nick Woolf - Chief Business Officer

Nick Woolf joined the company in September 2013. He is an accomplished business executive, bringing two decades of biotechnology and pharmaceutical industry experience to Suda. He has a strong track record in structuring, negotiating and executing successful alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organisations. Nick was most recently Chief Financial Officer and Vice President of Corporate Development of Phylogica Limited based in Western Australia. Prior to Phylogica, Nick was Chief Business Officer of a leading UK-based biopharmaceutical company, Oxford BioMedica plc. He began his career as a healthcare investment banker and was formerly head of European biotech equity research at ABN Amro. Mr Woolf holds a MA in Chemistry from Oxford University and is a qualified accountant.

 

Carol Worth - Technical Manager

Dr. Worth has been working in the area of drug delivery systems for over 25 years at various international companies. As a development chemist, she liaised between companies in USA, UK and Asia to develop oral formulations of injectable peptide hormones. She has since been involved in the development of novel anticancer drugs and, most recently, topical pain relief formulations. She has extensive experience in the setting up and running of GMP accredited laboratories and development of robust products suitable for GMP manufacturing. Dr. Worth has a PhD in Natural Product Chemistry from the University of Western Australia.